To investigate if HDAC3 could confer enhanced migratory and invasive capacities to gastric cancer cells, the migration and invasion were assessed using two distinct shRNAs targeting HDAC3 (shHDAC3 #267; #828) and the pharmacologic HDAC3 inhibitor RGFP966. This evidence concerns the gene HDAC3 and gastric cancer.